Trials Sponsors Conditions Drugs Pricing

Conditions

Diffuse Diseases

Outcome Measures

Primary Outcomes (1)

Index of reorganization of the structural hubs (ks-Degree)
5years

Secondary Outcomes (4)

Concentrations of sodium within hubs
5 years
Concentrations of Glutamate/Glutamine within hubs
5 years
cortical Thicknesses within hubs
5 years
Iron accumulation within hubs
5 years

Study Arms (6)

parkinson

EXPERIMENTAL

Device: MRI 7TDevice: MRI 3 T

partial epilepsy

EXPERIMENTAL

Device: MRI 7TDevice: MRI 3 T

alzheimer disease

EXPERIMENTAL

Device: MRI 7TDevice: MRI 3 T

Interventions

MRI 7TDevice

alzheimer diseaseamyotrophic lateral sclerosishealthy control patientsmultiple sclerosisparkinsonpartial epilepsy

MRI 3 TDevice

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Person female or male, more than 18-year-old,
Person presenting unchecked general disease such as severe cancer, autoimmune disease, hepatic insufficiency, severe or untreated, shady arterial high blood pressure of the conduction or the disorder of the rhythm

Sponsors & Collaborators

Assistance Publique Hopitaux De Marseille
Otherlead

Study Sites (1)

Assiatnce Publique Hopitaux de Marseille

Marseille, 13354, France

ALEXANDRA GIULIANICONTACTdrci@ap-hm.fr

MAXIME GUYEPRINCIPAL INVESTIGATOR

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

Catherine GEINDRE
Assistance Publique Hopitaux De Marseille
STUDY DIRECTOR

Central Study Contacts

maxime GUYE

CONTACT

maxime.guye@ap-hm.fr

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: DIAGNOSTIC
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 31, 2017

First Posted

February 1, 2017

Study Start

May 2017

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

February 2022

Estimated (date passed)

Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Study Arms (6)

parkinson

partial epilepsy

alzheimer disease

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

multiple sclerosis

amyotrophic lateral sclerosis

healthy control patients

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Study Arms (6)

parkinson

partial epilepsy

alzheimer disease

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

multiple sclerosis

amyotrophic lateral sclerosis

healthy control patients

You may not qualify if:

Data Sharing

Source record

Locations